Somewhat Favorable News Coverage Extremely Likely to Impact Biogen (NASDAQ:BIIB) Stock Price

News stories about Biogen (NASDAQ:BIIB) have been trending somewhat positive this week, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Biogen earned a news sentiment score of 1.08 on their scale. InfoTrie also assigned news stories about the biotechnology company an news buzz score of 10 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company’s share price in the next few days.

Here are some of the news stories that may have effected Biogen’s score:

NASDAQ:BIIB opened at $281.87 on Wednesday. Biogen has a 1 year low of $215.77 and a 1 year high of $344.00. The company has a current ratio of 2.46, a quick ratio of 2.22 and a debt-to-equity ratio of 0.49. The stock has a market cap of $40.59 billion, a price-to-earnings ratio of 10.76, a PEG ratio of 1.19 and a beta of 1.02. The stock has a 50-day moving average price of $229.69 and a two-hundred day moving average price of $231.20.

Biogen (NASDAQ:BIIB) last posted its earnings results on Tuesday, October 22nd. The biotechnology company reported $9.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.24 by $0.93. Biogen had a return on equity of 44.89% and a net margin of 37.62%. The firm had revenue of $3.60 billion during the quarter, compared to analysts’ expectations of $3.53 billion. During the same period in the previous year, the firm earned $7.40 earnings per share. The company’s revenue was up 4.7% on a year-over-year basis. Sell-side analysts forecast that Biogen will post 32.38 earnings per share for the current year.

A number of equities research analysts recently commented on the company. BidaskClub downgraded Biogen from a “hold” rating to a “sell” rating in a report on Saturday, October 12th. Cowen reiterated a “buy” rating and issued a $275.00 price objective on shares of Biogen in a report on Tuesday. Stifel Nicolaus reiterated a “hold” rating and issued a $296.00 price objective (up previously from $236.00) on shares of Biogen in a report on Tuesday. Piper Jaffray Companies reiterated a “hold” rating on shares of Biogen in a report on Friday, July 26th. Finally, Morgan Stanley upped their price objective on Biogen from $211.00 to $212.00 and gave the company an “underweight” rating in a report on Friday, October 11th. Five investment analysts have rated the stock with a sell rating, twenty-one have assigned a hold rating and six have given a buy rating to the company’s stock. Biogen has an average rating of “Hold” and an average price target of $271.92.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis.

Featured Story: Accumulation/Distribution

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.